Sebastian Fucile
Overview
Explore the profile of Sebastian Fucile including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chalmers J, Loebinger M, Teper A, McShane P, Fernandez C, Fucile S, et al.
ERJ Open Res
. 2025 Jan;
11(1.
PMID: 39872387
Introduction: Bronchiectasis is a chronic inflammatory airway disease. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), reduces pulmonary inflammation by preventing the activation of neutrophil serine proteases. In...
2.
Lapinel N, Choate R, Aksamit T, Feliciano J, Winthrop K, Schmid A, et al.
ERJ Open Res
. 2024 Nov;
10(6).
PMID: 39534769
Background: Exacerbations of noncystic fibrosis bronchiectasis (bronchiectasis) are associated with reduced health-related quality of life and increased mortality, likelihood of hospitalisation and lung function decline. This study investigated patient clinical...
3.
Feliciano J, Lewing B, Mohanty M, Lauterio M, Fucile S, Tkacz J, et al.
Pulm Ther
. 2024 Oct;
10(4):439-450.
PMID: 39390311
Introduction: There are limited real-world data on outcomes in patients with non-cystic fibrosis bronchiectasis (NCFBE). This study assessed clinical characteristics and survival in patients with NCFBE by baseline exacerbation rate....
4.
Tkacz J, Lewing B, Feliciano J, Mohanty M, Lauterio M, Fucile S, et al.
J Manag Care Spec Pharm
. 2024 Aug;
30(9):967-977.
PMID: 39213146
Background: Bronchiectasis carries a significant economic burden with high health care expenditures associated with frequent hospitalizations, physician visits, and treatments, including oral and intravenous antibiotics for repeated lung infections, airway-clearance...
5.
Aksamit T, Lapinel N, Choate R, Feliciano J, Winthrop K, Schmid A, et al.
Respir Med
. 2024 May;
228:107660.
PMID: 38734153
Background: This study aimed to evaluate the association between the number of non-cystic fibrosis bronchiectasis (bronchiectasis) exacerbations during baseline and follow-up (objective 1) and to identify longitudinal changes in FEV...
6.
Flume P, Feliciano J, Lucci M, Wu J, Fucile S, Hassan M, et al.
ERJ Open Res
. 2023 Jul;
9(4).
PMID: 37404848
Background: Patients with bronchiectasis experience persistent symptoms and frequent pulmonary exacerbations; this study investigated the frequency of exacerbations and all-cause hospitalisation. Methods: This longitudinal, retrospective, claims database study (IBM® MarketScan®)...
7.
Gessner C, Kornmann O, Maspero J, van Zyl-Smit R, Krull M, Salina A, et al.
Respir Med
. 2020 Oct;
175:106186.
PMID: 33082033
No abstract available.
8.
Gessner C, Kornmann O, Maspero J, van Zyl-Smit R, Krull M, Salina A, et al.
Respir Med
. 2020 Aug;
170:106021.
PMID: 32843164
Background: The efficacy and safety of once-daily (o.d.) fixed-dose combination of indacaterol (IND), glycopyrronium (GLY) and mometasone furoate (MF) via Breezhaler® versus concurrent administration of salmeterol/fluticasone (SAL/FLU) twice-daily (b.i.d.) via...
9.
Price D, Castro M, Bourdin A, Fucile S, Altman P
Eur Respir Rev
. 2020 Apr;
29(155).
PMID: 32245768
Short courses of systemic corticosteroids (SCS), both oral and injectable, are very effective for the resolution of acute asthma symptoms, including exacerbations. However, the benefits of SCS, even short courses,...
10.
Wedzicha J, Singh D, Tsiligianni I, Jenkins C, Fucile S, Fogel R, et al.
Respir Res
. 2019 Jan;
20(1):4.
PMID: 30621717
Background: The burden of chronic obstructive lung disease (COPD) is increasing in women, with recent evidence suggesting gender differences in disease characteristics and potentially in treatment outcomes. Methods: FLAME was...